NeuroSense to Showcase Clinical Developments on PrimeC at NEALS 2026 Conference

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a biopharmaceutical company focusing on innovative treatments for neurodegenerative disorders, is preparing for a significant presentation at the upcoming Annual Meeting of the Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium, scheduled for October 30th, 2026 in Clearwater, Florida. The presentation will spotlight the integration of clinical and biomarker data derived from the company's ongoing PARADIGM program, which is crucial for the upcoming Phase 3 clinical trial of PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis (ALS).

The session, aptly titled "From PARADIGM to PARAGON: Converging Clinical and Biomarker Findings Informing Phase 3 Development of PrimeC," is set to commence at 11:25 AM Eastern Time. Esteemed speakers for this session include Dr. Merit Cudkowicz, a prominent figure in ALS research and the Director of the Sean M. Healey AMG Center for ALS at Massachusetts General Hospital, alongside Dr. Shiran Zimri, Vice President of Research and Development at NeuroSense. This presentation is anticipated to elucidate how findings from the previous clinical trials are shaping a robust and efficient framework for advancing ALS treatments through the PrimeC platform.

The PrimeC initiative stands out as NeuroSense's flagship therapy, designed to address multiple biological pathways that contribute to the progression of neurodegenerative diseases. With PrimeC being an oral medication that combines two FDA-approved drugs, ciprofloxacin and celecoxib, the focus lies on its multi-target mechanism that aims to alleviate neuroinflammation, oxidative stress, and dysregulated iron metabolism—critical facets in the therapeutic landscape of ALS.

Recently published outcomes from the Phase 2b PARADIGM trial in JAMA Neurology highlight a notable deceleration in functional decline among participants administered PrimeC compared to those receiving a placebo. Furthermore, indicators of neural health, assessed through various biomarkers—including microRNAs—demonstrated changes consistent with the treatment's proposed multi-target action. Such data not only bolsters investor confidence but also sets a promising precedent for future clinical explorations.

In light of these pivotal developments, NeuroSense has secured FDA clearance to initiate the Phase 3 trial titled PARAGON, which will primarily take place across the United States. The focus remains on refining the study design in collaboration with regulatory bodies, ensuring an optimal approach to validating the therapeutic efficacy of PrimeC. As indications suggest that the prevalence of ALS cases may rise substantially over the coming years, effective treatment solutions like PrimeC could alter the trajectory of this challenging disease.

The urgency for effective ALS treatments has never been more pronounced, given the disease's devastating implications—affecting over 5,000 new patients annually in the U.S. alone, and resulting in significant healthcare burdens exceeding one billion dollars each year. The forecast indicates a 24% increase in ALS cases by 2040 in both the U.S. and Europe, enhancing the urgency for breakthroughs in treatment methodologies.

NeuroSense is committed to investing in robust clinical data to enhance PrimeC’s profile while broadening its potential applications within neurodegenerative medicine, including explorations into Alzheimer’s disease. As the NEALS 2026 Conference approaches, the biotech community watches eagerly to see how NeuroSense will leverage its findings to make impactful advancements in ALS treatment strategies.

Stay informed on further developments by following NeuroSense through their official website and social media platforms. The upcoming presentation promises to be an essential focal point for stakeholders invested in the future of neurodegeneration treatments.